TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07629206: Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)

Sponsor: IceCure Medical Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 400 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07629206 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07629206 Rescue Dossier →